GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InflaRx NV (NAS:IFRX) » Definitions » Operating Cash Flow per Share

InflaRx NV (InflaRx NV) Operating Cash Flow per Share : $-0.78 (TTM As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is InflaRx NV Operating Cash Flow per Share?

InflaRx NV's operating cash flow per share for the three months ended in Mar. 2024 was $-0.27. InflaRx NV's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.78.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 23.00% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 11.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for InflaRx NV's Operating Cash Flow per Share or its related term are showing as below:

IFRX' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -101.7   Med: -2.95   Max: 24
Current: 23

During the past 9 years, InflaRx NV's highest 3-Year average Operating Cash Flow per Share Growth Rate was 24.00% per year. The lowest was -101.70% per year. And the median was -2.95% per year.

IFRX's 3-Year OCF Growth Rate is ranked better than
71.74% of 1235 companies
in the Biotechnology industry
Industry Median: 3.5 vs IFRX: 23.00

InflaRx NV Operating Cash Flow per Share Historical Data

The historical data trend for InflaRx NV's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InflaRx NV Operating Cash Flow per Share Chart

InflaRx NV Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Cash Flow per Share
Get a 7-Day Free Trial Premium Member Only -1.85 -1.64 -1.08 -0.81 -0.75

InflaRx NV Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Operating Cash Flow per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.25 -0.21 -0.10 -0.20 -0.27

Competitive Comparison of InflaRx NV's Operating Cash Flow per Share

For the Biotechnology subindustry, InflaRx NV's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InflaRx NV's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InflaRx NV's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where InflaRx NV's Price-to-Operating-Cash-Flow falls into.



InflaRx NV Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

InflaRx NV's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )=Cash Flow from Operations (A: Dec. 2023 )/Shares Outstanding (Diluted Average) (A: Dec. 2023 )
=-41.236/54.940
=-0.75

InflaRx NV's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Mar. 2024 )=Cash Flow from Operations (Q: Mar. 2024 )/Shares Outstanding (Diluted Average) (Q: Mar. 2024 )
=-16.161/58.883
=-0.27

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InflaRx NV Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of InflaRx NV's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


InflaRx NV (InflaRx NV) Business Description

Industry
Traded in Other Exchanges
Address
Winzerlaer Strasse 2, Jena, DEU, 07745
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

InflaRx NV (InflaRx NV) Headlines

From GuruFocus

InflaRx to Present at the H.C. Wainwright Global Investment Conference

By GuruFocusNews GuruFocusNews 05-17-2022

InflaRx to Present at the H.C. Wainwright Global Investment Conference

By GuruFocusNews GuruFocusNews 05-27-2022